Negative Pressure Wound Therapy for the Treatment of Chronic Pressure Wounds

NCT ID: NCT00691821

Last Updated: 2011-07-26

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE4

Total Enrollment

184 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-04-30

Study Completion Date

2010-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to assess the difference in the percent reduction in wound surface area, without surgery, of chronic pressure ulcers of the pelvic region for Negative Pressure Wound Therapy (NPWT) compared to the standard dressing. This study is designed to provide evidence regarding NPWT as compared to standard dressing regimens and compare the efficacy, safety, effectiveness and cost-effectiveness.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The Ontario Health Technology Advisory Committee recommended that a study should be completed due to the large numbers of patients needing chronic wound care and the increasing use of NPWT based on poor quality evidence to identify any potential indications for the use of NPWT. This study is designed to provide evidence regarding NPWT as compared to standard dressing regimens in Ontario and the results will serve as a benchmark for the utilization of NPWT in chronic pressure wounds, establishing and providing guidance regarding the use of NPWT in this population of subjects and to support policy decision making regarding the funding of the NPWT in the province. Specifically, this will compare the efficacy, effectiveness and cost-effectiveness of NPWT with standard dressing regimens for the treatment of chronic pressure ulcers of the pelvic region.

This is a prospective, randomized, open-label, controlled clinical trial comparing standardized wound dressing (control arm) to NPWT (experimental arm) for the treatment of chronic pressure wounds of the pelvic region. NPWT will be performed using the Vacuum-Assisted Closure System (V.A.C.® Therapy™, KCI Medical Canada Inc., Mississauga, Ontario). NPWT will be compared to the present recommended state of the art wound dressings in subjects who would be candidates for either type of wound therapy. Both arms will receive standard wound care (e.g., debridement, preventative care, infection control, etc.). The efficacy, effectiveness, safety, and quality of life will be evaluated for standardized wound dressing versus NPWT. Complications associated with either form of wound care will be documented. An economic evaluation will be conducted in order to assess the cost-effectiveness and cost-utility of NPWT compared to standard wound dressing. It is anticipated that 184 subjects will be enrolled and randomized over a 1.5 year period. All subjects providing consent and meeting inclusion/exclusion criteria will be randomized to either treatment arm and followed for 12 weeks. Patients who have wound closure within the 12-week study period will continue to have wound care visits as scheduled. All subjects will have Wound Evaluation Visits and Wound Dressing Change Visits. Wound Evaluation Visits will occur at baseline, 2, 4, 6, 8 and 12 weeks after the date of randomization, where following removal of the dressing, a detailed wound assessment (e.g., wound characteristics, measurements) will be done and healthcare resource utilization will be collected. Disease specific quality of life measures and preference based quality of life measures (EQ-5D) will be collected at baseline, 6 weeks and at 12 weeks. Dressing Change Visits will occur as clinically required and the frequency of dressing changes per week will be allowed to vary over the 12 weeks of the study. During the dressing change visits, subjects will be monitored for wound infection and other complications. Subjects may be enrolled and randomized in the clinic and transferred to the community with continued follow-up completed by the appropriate Community Care Access Centre.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Skin Ulcer Pressure Ulcer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Standard Dressings

Group Type ACTIVE_COMPARATOR

Standard Dressings

Intervention Type OTHER

Participants will receive standard dressings changes as needed. Different dressing types (e.g., silver, simple gauze, hydrogel, foam, creams, gels) will be used dependent on the type of the wound (e.g., dry, wet, and intermediate).

2

Negative Pressure Wound Therapy

Group Type EXPERIMENTAL

Negative Pressure Wound Therapy (Vacuum-Assisted Closure System [V.A.C.® Therapy™, KCI Medical Canada Inc., Mississauga, Ontario])

Intervention Type DEVICE

Participants will receive negative pressure wound therapy.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Standard Dressings

Participants will receive standard dressings changes as needed. Different dressing types (e.g., silver, simple gauze, hydrogel, foam, creams, gels) will be used dependent on the type of the wound (e.g., dry, wet, and intermediate).

Intervention Type OTHER

Negative Pressure Wound Therapy (Vacuum-Assisted Closure System [V.A.C.® Therapy™, KCI Medical Canada Inc., Mississauga, Ontario])

Participants will receive negative pressure wound therapy.

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

V.A.C. Therapy

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Age \> 18 years
2. All chronic pressure wounds of the pelvic region except trochanteric wounds.
3. Chronic pressure wound defined as the presence of a pressure wound for \> 6 weeks and \< 6 months with no sign of improvement in healing
4. Wound size surface area \> 2cm2
5. Stage III-IV pressure ulcer according to the National Pressure Ulcer Advisory Panel (NPUAP)
6. No clinical signs of active infection at the wound site and currently not on antibiotics
7. Willingness to off-load or pressure redistribute ulcer

Exclusion Criteria

1. Candidate for surgery in the next 12 weeks
2. A wound with necrotic tissue unable to tolerate debridement
3. Exposed blood vessels and/or organs within the wound
4. Chronic osteomyelitis (as determined by biopsy) or osteomyelitis that is not treatable by debridement and antibiotics
5. Non-enteric or unexplored fistulae
6. Wounds requiring hemostasis (i.e., that the flow of blood be stopped) for local bleeding
7. Alternate etiology for non-healing
8. Concomitant conditions that in the judgment of the investigator would make the subject inappropriate for entry to the study (e.g., malignancy in wound, malignancy less than 1-year disease free interval, previous or current irradiation, known immunodeficiency and/or major uncorrected medical disorders such as serious non-malignant disease, serious cardiovascular or pulmonary disease, lupus, inflammatory bowel disease, palliative care or sickle cell disease)
9. Poor nutritional status as determined by a Braden Scale Nutritional Assessment score of 2 or 1 with a serum albumin \< 25 g/L and hemoglobin \< 90 g/L
10. Currently taking medication that may interfere with wound healing (e.g., oral systemic steroids, immunosuppressive drugs, unfractionated heparin infusion)
11. Women who are currently pregnant or are breast feeding; or women of child bearing potential who are not currently taking adequate birth control
12. Participation in another investigative drug or device trial currently or within the last 30 days
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Ontario Ministry of Health and Long Term Care

OTHER_GOV

Sponsor Role collaborator

Unity Health Toronto

OTHER

Sponsor Role collaborator

Women's College Hospital

OTHER

Sponsor Role collaborator

Hamilton Niagara Haldimand Brant Community Care Access Centre

OTHER

Sponsor Role collaborator

Toronto Central Community Care Access Centre

OTHER

Sponsor Role collaborator

St. Joseph's Healthcare Hamilton

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Programs for Assessment of Technology in Health (PATH) Research Institute

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Ron Goeree, MA

Role: STUDY_CHAIR

Programs for Assessment of Technology in Health Research Institute

James Mahoney, MD

Role: PRINCIPAL_INVESTIGATOR

Unity Health Toronto

Gary Sibbald, MD

Role: PRINCIPAL_INVESTIGATOR

Women's College

Maureen Kitson

Role: PRINCIPAL_INVESTIGATOR

Niagara Region Community Care Access Centre

Joanne Greco, BScN

Role: PRINCIPAL_INVESTIGATOR

Toronto Central Community Care Access Centre

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Niagara Branch - Hamilton Niagara Haldimand Brant Community Care Access Centre

Saint Catherines, Ontario, Canada

Site Status

St. Michael's Hospital

Toronto, Ontario, Canada

Site Status

Women's College Hospital

Toronto, Ontario, Canada

Site Status

Toronto Central Community Care Access Centre

Toronto, Ontario, Canada

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Canada

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

HTA012-0801-01

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

VAC Bioburden Wound Care Assessment
NCT04826965 TERMINATED NA